Skip to main content
Swing Capital

Kopran Ltd

NSE: KOPRAN BSE: 524280Pharma

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

₹166
52W: ₹107 — ₹213
PE 39.5 · Book ₹86.3 · +92% vs book
Market Cap₹801 Cr
Stock P/E39.5Price to Earnings
ROCE8.63%Return on Capital
ROE6.33%Return on Equity
Div. Yield1.83%Face Value ₹10

Strengths

  • +Company has delivered good profit growth of 19.0% CAGR over last 5 years
  • +Company has been maintaining a healthy dividend payout of 47.3%

Weaknesses

  • −The company has delivered a poor sales growth of 8.61% over past five years.
  • −Company has a low return on equity of 7.62% over last 3 years.

Shareholding Pattern

Promoters44.43%
FIIs0.57%
DIIs0%
Public55.01%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters44.49%44.49%44.45%▼0.044.42%▼0.044.43%▲0.044.43%44.43%44.43%
FIIs0.68%1.31%▲0.60.86%▼0.51.11%▲0.30.76%▼0.40.6%▼0.20.36%▼0.20.57%▲0.2
DIIs0.14%0.22%▲0.10%▼0.20%0%0%0%0%
Public54.68%53.98%▼0.754.68%▲0.754.45%▼0.254.81%▲0.454.99%▲0.255.21%▲0.255.01%▼0.2

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales99829150747276514294
Expenses90707544646164464676
Operating Profit9121551011125-318
OPM %9%15%17%11%13%16%16%10%-8%19%
Net Profit1191547794-412
EPS ₹2.211.773.180.881.371.541.780.73-0.832.51

AI Insights

Revenue Trend

TTM revenue at ₹264Cr, down 2.6% YoY. OPM at 12%.

Debt Position

Borrowings at ₹46Cr. Debt-to-equity ratio: 0.13x. Healthy balance sheet.

Capex Cycle

CWIP at ₹6Cr (8% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 0% (-0.14pp change). FIIs: 0.57% (+0.23pp change). Promoters hold 44.43%.

Margin & Efficiency

ROCE declining from 11% (Mar 2014) to 9% (Mar 2025). Working capital days: 114.

Valuation

PE 39.5x with 8.63% ROCE. Price is 92% above book value of ₹86.3. Dividend yield: 1.83%.

Recent Announcements